17847-40-4

Usage

Uses

Used in Pharmaceutical Industry:
(3,4-DICHLORO-PHENYL)-ETHYL-AMINE is used as a potential pharmaceutical agent for the treatment of neurological and psychiatric disorders. Its structural similarity to amphetamine and psychoactive properties suggest that it may have therapeutic applications in this field.
Used in Research and Development:
(3,4-DICHLORO-PHENYL)-ETHYL-AMINE is used as a subject of research for understanding its potential as a psychotherapeutic aid. Further studies are required to explore its efficacy, safety profile, and therapeutic potential in various conditions.

Upstream product

• 2150-93-8 N-(3,4-dichlorophenyl)acetamide 
• 95-76-1 m,p-dichloroaniline 

Downstream Products

• 16505-72-9 N-Butyryl-N-aethyl-3,4-dichlor-anilin 
• 16505-71-8 N-Acetyl-N-aethyl-3,4-dichlor-anilin 
• 15533-87-6 N-Propionyl-N-aethyl-3,4-dichlor-anilin 
• 67103-23-5 (3,4-Dichloro-phenyl)-ethyl-carbamic acid 3-prop-2-ynyloxycarbonylamino-phenyl ester 
• 55239-41-3 C₉H₈Cl₃NO 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Ru-Catalyzed Deoxygenative Transfer Hydrogenation of Amides to Amines with Formic Acid/Triethylamine

A ruthenium(II)-catalyzed deoxygenative transfer hydrogenation of amides to amines using HCO2H/NEt3 as the reducing agent is reported for the first time. The catalyst system consisting of [Ru(2-methylallyl)2(COD)], 1,1,1-tris(diphenylphosphinomethyl) ethane (triphos) and Bis(trifluoromethane sulfonimide) (HNTf2) performed well for deoxygenative reduction of various secondary and tertiary amides into the corresponding amines in high yields with excellent selectivities, and exhibits high tolerance toward functional groups including those that are reduction-sensitive. The choice of hydrogen source and acid co-catalyst is critical for catalysis. Mechanistic studies suggest that the reductive amination of the in situ generated alcohol and amine via borrowing hydrogen is the dominant pathway. (Figure presented.).

Zirconium borohydride - A versatile reducing agent for the reduction of electrophilic and nucleophilic substrates

Zirconium borohydride, a potential reducing agent, reduces acids, esters, imines to the corresponding alcohols and secondary amines in good yield at room temperature within two hours. This facile reducing property was taken advantage off in the synthesis of pheromones and some novel chiral precursors for asymmetric synthesis.

Unusual reactivity of zinc borohydride - Reduction of amides to amines

Zinc borohydride reduces secondary amides to the corresponding N-ethyl amines in excellent yields. The reduction requires only stoichiometric quantities of hydride and does not require the addition of any Lewis acid. The amides are isolated by simple hydrolysis of the reaction mixture.